Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01416441 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Tourette's Disorder

Interventions

DRUG: Aripiprazole

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.